E 6201

Drug Profile

E 6201

Alternative Names: E6201

Latest Information Update: 10 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eisai Medical Research
  • Developer Eisai Co Ltd; Strategia Therapeutics; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Lactones; Resorcinols
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; MAP kinase kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Phase I Solid tumours
  • Discontinued Plaque psoriasis

Most Recent Events

  • 09 Nov 2017 Chemical structure added
  • 09 Nov 2017 Strategia Therapeutics and University of Arizona plan a phase I trial for Brain metastases and Malignant melanoma (Metastatic disease) in USA in January 2018 (NCT03332589)
  • 31 Aug 2017 E 6201 is still in phase I/II trials for Chronic myelomonocytic leukaemia, Myelodysplastic syndromes and Acute myeloid leukaemia (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT02418000)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top